Sanofi dumps otamixaban and iniparib on PhIII failures
This article was originally published in Scrip
Sanofi has dropped development of its investigational anticancer iniparib and Factor Xa inhibitor otamixaban after both drugs failed in Phase III trials. In the case of iniparib, the assets are to be fully impaired on the 30 June balance sheet, knocking $285 million off net income.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.